Diagnosis of Parkinson's Disease in Patients with and without Dementia

Summary of the technology

Blood gene transcripts may identify Parkinson's disease patients with and without dementia
Project ID : 46-2019-10785

Yissum - Research Development Company of the Hebrew University

Details of the Technology Offer


LifeSciences and BioTechnology


Parkinson’s Disease, PD, Dementia, Diagnostic Kit, Diagnostics, Non-Motor Symptoms, mRNA, Circulating RNA

Current development stage

General list: TRL3 Experimental proof of concept


Parkinson's disease (PD) is the second most common neurodegenerative disease, with an expected 9 million patients worldwide by 2030. Currently, treatment for PD mainly consists of dopamine substitution with L-Dopa, aiming to alleviate the motor symptoms of the disease, which are believed to be caused by the death of dopaminergic neurons in the Substantia Nigra.

The diagnosis of Parkinson's disease relies on expert opinion. Studies, however, have demonstrated that even experienced neurologists misdiagnose Parkinson's disease in about a quarter out of every one hundred cases. Diagnostic accuracy at disease onset, when neuroprotective treatment is purported to be most effective, is even lower; typically, at diagnosis, 70% of dopaminergic neurons have already died and the available treatment can only limit symptoms rather than achieve remission. Thus, there is a crucial need for biomarkers that are disease-specific and which precisely identify the disease course as early as possible. Additionally, part of the PD patients have dementia, but at present there is no objective diagnosis to identify them.

Circulating RNAs have been researched in recent years as an upcoming biomarker in PD. In particular, previous research raised several promising candidates for biomarkers of the disease, however, identifying clinically relevant rare circular RNAs and small non-coding RNA candidates such as microRNAs is rather complex, making the construction of an easy diagnosis tool for clinical use very difficult.

Our Innovation

We have discovered novel blood biomarkers that can differentiate between Parkinson’s disease patients with and without dementia. These biomarkers can be used to develop a diagnostic kit that can implicate treatment protocols and can also be used as a tool for companion diagnostics for drug development companies.


The current project is based on the use of mRNA transcripts from nucleated blood cells to differentiate between PD patients with and without dementia and using age-matched controls. It is based on comparing whole blood mRNA transcripts by RNA- sequencing, instead of restricting methods like microarrays and qPCR. This provides accesses to all mRNA transcripts in the blood, as well as to all long non-coding RNAs. Use of technology for clinical diagnostic kit will not require tailored microarrays based on these sequencing results and will be based on the identified biomarkers.


  • Our invention can be used as a diagnostic tool for differentiating PD patients with or without dementia. Such differentiation may support clinician’s decisions in early stages and thus contribute to better and precise treatment.
  • Companion diagnostics:
  • Selection of sub-populations of PD patients for clinical trial recruitment
  • Collaboration with drug development companies

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Hermona Soreq
HUJI, Faculty of Science
The Alexander Silberman Institute for Life Sciences

Related Keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Biomarkers
  • Life Science & Biotechnology
  • parkinson
  • dementia

About Yissum - Research Development Company of the Hebrew University

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Yissum - Research Development Company of the Hebrew University

Never miss an update from Yissum - Research Development Company of the Hebrew University

Create your free account to connect with Yissum - Research Development Company of the Hebrew University and thousands of other innovative organizations and professionals worldwide

Yissum - Research Development Company of the Hebrew University

Send a request for information
to Yissum - Research Development Company of the Hebrew University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support